Previous studies have indicated that AZGP1 possesses zinc-binding properties and its expression is reduced in more aggressive cancer lesions, such as PCa, breast cancer, colon cancer, liver cancer, gastric cancer, and lung cancer [7–11]. Here, AZGP1 is linked to breast cancer.